[go: up one dir, main page]

MX2016000290A - Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion. - Google Patents

Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion.

Info

Publication number
MX2016000290A
MX2016000290A MX2016000290A MX2016000290A MX2016000290A MX 2016000290 A MX2016000290 A MX 2016000290A MX 2016000290 A MX2016000290 A MX 2016000290A MX 2016000290 A MX2016000290 A MX 2016000290A MX 2016000290 A MX2016000290 A MX 2016000290A
Authority
MX
Mexico
Prior art keywords
anticholinergic
corticosteroid
inhalation
dry powder
adrenergic
Prior art date
Application number
MX2016000290A
Other languages
English (en)
Inventor
Irene Pasquali
Rossella Musa
Azita Askey-Sarvar
Francesca Schiaretti
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51292914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2016000290(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of MX2016000290A publication Critical patent/MX2016000290A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Reciprocating Pumps (AREA)

Abstract

Formulaciones en polvo seco para inhalación, que comprenden una combinación de un anticolinérgico, un agonista del adrenorreceptor beta2 de larga acción y un corticosteroide, su proceso de preparación y usos terapéuticos de los mismos.
MX2016000290A 2013-07-11 2014-07-10 Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion. MX2016000290A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13176114 2013-07-11
EP13194763 2013-11-28
PCT/EP2014/064824 WO2015004243A1 (en) 2013-07-11 2014-07-10 Dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic for administration by inhalation

Publications (1)

Publication Number Publication Date
MX2016000290A true MX2016000290A (es) 2016-04-13

Family

ID=51292914

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000290A MX2016000290A (es) 2013-07-11 2014-07-10 Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion.

Country Status (35)

Country Link
US (2) US9402825B2 (es)
EP (3) EP3569222B1 (es)
JP (1) JP6426167B2 (es)
KR (2) KR102275904B1 (es)
CN (1) CN105338960B (es)
AR (1) AR129501A2 (es)
AU (1) AU2014289185B2 (es)
BR (1) BR112015030914B1 (es)
CA (1) CA2917752C (es)
CL (1) CL2016000028A1 (es)
CY (2) CY1120806T1 (es)
DK (3) DK3409270T3 (es)
EA (1) EA029125B1 (es)
ES (3) ES2699986T3 (es)
FI (1) FI3569222T3 (es)
GE (2) GEP20186853B (es)
HR (3) HRP20241300T1 (es)
HU (3) HUE068270T2 (es)
IL (1) IL243507A0 (es)
LT (3) LT3569222T (es)
MX (1) MX2016000290A (es)
MY (1) MY176176A (es)
NZ (1) NZ715797A (es)
PE (2) PE20160372A1 (es)
PH (1) PH12016500043B1 (es)
PL (3) PL3019153T3 (es)
PT (1) PT3019153T (es)
RS (3) RS57799B1 (es)
SA (1) SA516370373B1 (es)
SG (1) SG11201600110RA (es)
SI (3) SI3569222T1 (es)
TN (1) TN2016000007A1 (es)
TW (1) TWI642450B (es)
UA (1) UA116907C2 (es)
WO (1) WO2015004243A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2515855T6 (da) * 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
HUE060421T2 (hu) * 2012-01-25 2023-02-28 Chiesi Farm Spa Kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény inhalálással történõ beadásra
ES2699986T3 (es) * 2013-07-11 2019-02-13 Chiesi Farm Spa Formulación de polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación
GB201321717D0 (en) * 2013-12-09 2014-01-22 Pharmachemie Bv Inhalable Medicaments
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
JP6600961B2 (ja) * 2015-03-30 2019-11-06 ブラザー工業株式会社 表示制御装置、表示制御方法及び記憶媒体
US20180147161A1 (en) * 2015-05-01 2018-05-31 Board Of Regents, The University Of Texas System Multidrug brittle matrix compositions
AR106687A1 (es) * 2015-11-16 2018-02-07 Chiesi Farm Spa PROCESO PARA PREPARAR UNA FORMULACIÓN EN POLVO SECO QUE COMPRENDE UN ANTICOLINÉRGICO, UN CORTICOSTEROIDE Y UN b-ADRENÉRGICO
LT3377108T (lt) 2015-11-16 2020-07-10 Chiesi Farmaceutici S.P.A. Inhaliacinių miltelių kompozicijos, apimančios anticholinerginį agentą, kortikosteroidą ir beta adrenerginį agentą, paruošimo būdas
CA3062126C (en) 2016-11-10 2021-04-27 Medisca Pharmaceutique Inc. Container assembly and adapter therefor
CN110582269B (zh) * 2017-05-11 2023-02-28 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
US10350164B2 (en) 2017-05-11 2019-07-16 Chiesi Farmaceutici S.P.A. Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
CN109200034A (zh) * 2017-06-30 2019-01-15 正大天晴药业集团股份有限公司 一种可吸入干粉形式的组合物及其制备方法
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
AU2020356243A1 (en) * 2019-09-24 2022-03-24 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation
US12029709B2 (en) * 2022-08-11 2024-07-09 De Motu Cordis Pty Ltd Inhalable epinephrine formulation

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ511527A (en) * 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
JP5698423B2 (ja) * 2000-06-27 2015-04-08 ベクトゥラ・リミテッド 医薬組成物で使用するための粒子の製造法
PT2283817T (pt) * 2000-11-30 2016-08-22 Vectura Ltd Método de fabrico de partículas para utilização numa composição farmacêutica
EP1658872B2 (en) 2002-07-31 2019-08-21 CHIESI FARMACEUTICI S.p.A. Powder inhaler
JO3102B1 (ar) * 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0613161D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
WO2011076841A2 (en) 2009-12-23 2011-06-30 Chiesi Farmaceutici S.P.A. Combination therapy for copd
DK2515855T6 (da) 2009-12-23 2023-06-06 Chiesi Farm Spa Kombinationsterapi til COPD
TR201000681A2 (tr) 2010-01-29 2011-08-22 B�Lg�� Mahmut İnhalasyon yoluyla alınan kuru toz formülasyonları.
PL2552424T3 (pl) 2010-04-01 2018-10-31 Chiesi Farmaceutici S.P.A. Sposób wytwarzania cząstek nośnika do suchych proszków do inhalacji
HRP20180488T1 (hr) * 2010-04-21 2018-07-13 Chiesi Farmaceutici S.P.A. Postupak priprave čestica sa smanjenim elektrostatičkim nabojem
CA2803418A1 (en) * 2010-06-22 2011-12-29 Chiesi Farmaceutici S.P.A. Dry powder formulation comprising an antimuscarinic drug
HUE060421T2 (hu) * 2012-01-25 2023-02-28 Chiesi Farm Spa Kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény inhalálással történõ beadásra
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
ES2699986T3 (es) * 2013-07-11 2019-02-13 Chiesi Farm Spa Formulación de polvo seco que comprende un anticolinérgico, un corticosteroide y un betaadrenérgico para administración por inhalación

Also Published As

Publication number Publication date
AU2014289185B2 (en) 2019-05-23
RS61652B1 (sr) 2021-04-29
US9402825B2 (en) 2016-08-02
HUE068270T2 (hu) 2024-12-28
EA029125B1 (ru) 2018-02-28
PT3019153T (pt) 2018-12-04
PH12016500043A1 (en) 2016-03-28
ES2986128T3 (es) 2024-11-08
US9808422B2 (en) 2017-11-07
CY1123937T1 (el) 2022-05-27
CY1120806T1 (el) 2019-12-11
NZ715797A (en) 2020-06-26
HUE053957T2 (hu) 2021-08-30
GEP20186853B (en) 2018-05-25
BR112015030914B1 (pt) 2023-04-04
SG11201600110RA (en) 2016-02-26
PE20212110A1 (es) 2021-11-04
AR129501A2 (es) 2024-09-04
DK3019153T3 (en) 2018-11-19
PE20160372A1 (es) 2016-05-19
SI3019153T1 (sl) 2018-12-31
AU2014289185A1 (en) 2016-02-04
SI3569222T1 (sl) 2024-10-30
DK3569222T3 (da) 2024-08-19
CA2917752A1 (en) 2015-01-15
ES2867552T3 (es) 2021-10-20
PH12016500043B1 (en) 2018-11-23
LT3019153T (lt) 2018-11-26
RS65951B1 (sr) 2024-10-31
SI3409270T1 (sl) 2021-07-30
KR102275904B1 (ko) 2021-07-13
BR112015030914A2 (es) 2017-07-25
CN105338960B (zh) 2019-06-04
PL3569222T3 (pl) 2024-10-28
FI3569222T3 (fi) 2024-09-24
EP3569222B1 (en) 2024-06-26
EP3019153B1 (en) 2018-09-05
EA201690006A1 (ru) 2016-07-29
HRP20241300T1 (hr) 2024-12-06
US20160263027A1 (en) 2016-09-15
HUE039827T2 (hu) 2019-02-28
ES2699986T3 (es) 2019-02-13
JP2016523950A (ja) 2016-08-12
HK1218712A1 (zh) 2017-03-10
CN105338960A (zh) 2016-02-17
LT3569222T (lt) 2024-09-25
UA116907C2 (uk) 2018-05-25
WO2015004243A1 (en) 2015-01-15
EP3019153A1 (en) 2016-05-18
EP3409270A1 (en) 2018-12-05
PL3019153T3 (pl) 2019-02-28
KR20210075217A (ko) 2021-06-22
EP3569222A1 (en) 2019-11-20
GEAP201814032A (en) 2018-01-25
RS57799B1 (sr) 2018-12-31
HRP20182008T1 (hr) 2019-01-25
KR20160029797A (ko) 2016-03-15
TWI642450B (zh) 2018-12-01
HRP20210704T1 (hr) 2021-06-11
JP6426167B2 (ja) 2018-11-21
IL243507A0 (en) 2016-02-29
SA516370373B1 (ar) 2017-10-11
US20150017248A1 (en) 2015-01-15
DK3409270T3 (da) 2021-04-26
TW201536352A (zh) 2015-10-01
MY176176A (en) 2020-07-24
EP3409270B1 (en) 2021-02-24
CA2917752C (en) 2022-05-03
LT3409270T (lt) 2021-07-26
PL3409270T3 (pl) 2021-08-09
CL2016000028A1 (es) 2016-08-05
TN2016000007A1 (en) 2017-07-05

Similar Documents

Publication Publication Date Title
MX2016000290A (es) Formulacion en polvo seco que comprende un anticolinergico, un corticosteroide y un beta-adrenergico para administrar por inhalacion.
CL2015000530A1 (es) Compuestos derivados ciclicos eter pirazol-4-il-heterociclil-carboxamida, como inhibidores de la quinasa pim; composicion farmaceutica que los comprende; y su uso para el tratamiento de cancer, trastornos inmunologicos, enfermedades cardiovasculares, infeccion virica, inflamacion, trastornos del metabolismo/funcion endocrina y trastornos neurologicos.
UY36342A (es) Nuevos derivados de aminoalquilbenzotiazepinas y usos de los mismos
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
CL2015000744A1 (es) Combinación de regorafenib y ácido acetilsalicílico para el tratamiento del cáncer.
PE20151416A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
CR20170076A (es) Derivados de pirimidima sustituidos con heterociclilo opcionalmente condensados útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
MX2016007410A (es) Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas.
CO2018005141A2 (es) Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico
CO2017008031A2 (es) Compuestos con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
CO2018005139A2 (es) Proceso para preparar una formulación en polvo seco que comprende un anticolinérgico, un corticosteroide y un beta-adrenérgico
CO2017006958A2 (es) Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para la preparación y uso de los mismos
CR20160084A (es) Derivados de amida como agonistas del receptor del ácido lisofosfatídico
CL2018003338A1 (es) Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant.
UY35876A (es) Derivados de pirazolopirimidin-2-ilo como inhibidores de jak
CL2016000397A1 (es) Tratamiento contra el cáncer
MX376160B (es) Compuestos que tienen actividad antagonista del receptor muscarínico y actividad agonista del receptor beta2 adrenérgico.
UY35672A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos
PT3569222T (pt) Formulação em pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação
TH1401007646A (th) รูปแบบยาเวชภัณฑ์สำหรับการปลดปล่อยส่วนประกอบออกฤทธิ์ (Medicament form for release of active ingredients)

Legal Events

Date Code Title Description
FG Grant or registration